|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arnold M, Soerjomataram I, Ferlay J and
Forman D: Global incidence of oesophageal cancer by histological
subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Medical Research Council Oesophageal
Cancer Working Group, : Surgical resection with or without
preoperative chemotherapy in oesophageal cancer: A randomised
controlled trial. Lancet. 359:1727–1733. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shapiro J, van Lanschot JJB, Hulshof MCCM,
van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven
HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al:
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for
oesophageal or junctional cancer (CROSS): Long-term results of a
randomised controlled trial. Lancet Oncol. 16:1090–1098. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vellayappan BA, Soon YY, Ku GY, Leong CN,
Lu JJ and Tey JC: Chemoradiotherapy versus chemoradiotherapy plus
surgery for esophageal cancer. Cochrane Database Syst Rev.
8:CD0105112017.PubMed/NCBI
|
|
9
|
van't Veer LJ, Dai H, van de Vijver MJ, He
YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van de Vijver MJ, He YD, van't Veer LJ,
Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C,
Marton MJ, et al: A gene-expression signature as a predictor of
survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang JC, Wooten EC, Tsimelzon A,
Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK,
Chamness GC, Allred DC and O'Connell P: Gene expression profiling
for the prediction of therapeutic response to docetaxel in patients
with breast cancer. Lancet. 362:362–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beer DG, Kardia SL, Huang CC, Giordano TJ,
Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al:
Gene-expression profiles predict survival of patients with lung
adenocarcinoma. Nat Med. 8:816–824. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu Y, Lemon W, Liu PY, Yi Y, Morrison C,
Yang P, Sun Z, Szoke J, Gerald WL, Watson M, et al: A gene
expression signature predicts survival of patients with stage I
non-small cell lung cancer. PLoS Med. 3:e4672006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ghadimi BM, Grade M, Difilippantonio MJ,
Varma S, Simon R, Montagna C, Füzesi L, Langer C, Becker H, Liersch
T, et al: Effectiveness of gene expression profiling for response
prediction of rectal adenocarcinomas to preoperative
chemoradiotherapy. J Clin Oncol. 23:1826–1838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu P, Qiao J, He W, Wang J, Jia Y, Sun Y,
Tang S, Fu L and Qin Y: Genome-wide gene expression profile
analyses identify CTTN as a potential prognostic marker in
esophageal cancer. PLoS One. 9:e889182014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sugito N, Ishiguro H, Kuwabara Y, Kimura
M, Mitsui A, Kurehara H, Ando T, Mori R, Takashima N, Ogawa R and
Fujii Y: RNASEN regulates cell proliferation and affects survival
in esophageal cancer patients. Clin Cancer Res. 12:7322–7328. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ceccarelli M, Barthel FP, Malta TM,
Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh
A, Pagnotta SM, et al: Molecular profiling reveals biologically
discrete subsets and pathways of progression in diffuse glioma.
Cell. 164:550–563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Choi W, Porten S, Kim S, Willis D, Plimack
ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al:
Identification of distinct basal and luminal subtypes of
muscle-invasive bladder cancer with different sensitivities to
frontline chemotherapy. Cancer Cell. 25:152–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Damrauer JS, Hoadley KA, Chism DD, Fan C,
Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS and
Kim WY: Intrinsic subtypes of high-grade bladder cancer reflect the
hallmarks of breast cancer biology. Proc Natl Acad Sci USA.
111:3110–3115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo X, Jo VY, Mills AM, Zhu SX, Lee CH,
Espinosa I, Nucci MR, Varma S, Forgó E, Hastie T, et al: Clinically
relevant molecular subtypes in leiomyosarcoma. Clin Cancer Res.
21:3501–3511. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lapointe J, Li C, Higgins JP, Van De Rijn
M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim
U, et al: Gene expression profiling identifies clinically relevant
subtypes of prostate cancer. Proc Natl Acad Sci USA. 101:811–816.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu J, Dang H and Wang XW: The
significance of intertumor and intratumor heterogeneity in liver
cancer. Exp Mol Med. 50:e4162018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee WC, Diao L, Wang J, Zhang J, Roarty
EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, et al:
Multiregion gene expression profiling reveals heterogeneity in
molecular subtypes and immunotherapy response signatures in lung
cancer. Mod Pathol. 31:947–955. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rouzier R, Perou CM, Symmans WF, Ibrahim
N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P,
et al: Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–1885. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szász AM, Lánczky A, Nagy Á, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Győrffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Staff PO: Correction: Online survival
analysis software to assess the prognostic value of biomarkers
using transcriptomic data in non-small-cell lung cancer. PLoS One.
9:e1118422014. View Article : Google Scholar
|
|
30
|
Li J, Chen Z, Tian L, Zhou C, He MY, Gao
Y, Wang S, Zhou F, Shi S, Feng X, et al: LncRNA profile study
reveals a three-lncRNA signature associated with the survival of
patients with oesophageal squamous cell carcinoma. Gut.
63:1700–1710. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cancer Genome Atlas Research Network,
Analysis Working Group: Asan University; BC Cancer Agency; Brigham
and Women's Hospital; Broad Institute; Brown University; Case
Western Reserve University; Dana-Farber Cancer Institute; Duke
University; Greater Poland Cancer Centre, et al, . Integrated
genomic characterization of oesophageal carcinoma. Nature.
541:169–175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang J, Zhou Y, Wu YJ, Li MJ, Wang RJ,
Huang SQ, Gao RR, Ma L, Shi HJ and Zhang J: Hyper-methylated
miR-203 dysregulates ABL1 and contributes to the nickel-induced
tumorigenesis. Toxicol Lett. 223:42–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Makino H, Tajiri T, Miyashita M, Sasajima
K, Anbazhagan R, Johnston J and Gabrielson E: Differential
expression of TCEAL1 in esophageal cancers by custom cDNA
microarray analysis. Dis Esophagus. 18:37–40. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang J, Wang K, Zhang J, Liu SS, Dai L
and Zhang JY: Using proteomic approach to identify tumor-associated
proteins as biomarkers in human esophageal squamous cell carcinoma.
J Proteome Res. 10:2863–2872. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yan Y, Fan Q, Wang L, Zhou Y, Li J and
Zhou K: LncRNA Snhg1, a non-degradable sponge for miR-338, promotes
expression of proto-oncogene CST3 in primary esophageal cancer
cells. Oncotarget. 8:35750–35760. 2017.PubMed/NCBI
|
|
37
|
Zhu X, Zou S, Zhou J, Zhu H, Zhang S,
Shang Z, Ding WQ, Wu J and Chen Y: REV3L, the catalytic subunit of
DNA polymerase ζ, is involved in the progression and
chemoresistance of esophageal squamous cell carcinoma. Oncol Rep.
35:1664–1670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu H, Zhang H and Feng C: Over-expression
of PLAU regulates the radiosensitivity of esophageal cancer cell.
Int J Clin Exp Pathol. 9:10020–10027. 2016.
|
|
39
|
Clavier JB, Antoni D, Atlani D, Ben
Abdelghani M, Schumacher C, Dufour P, Kurtz JE and Noel G: Baseline
nutritional status is prognostic factor after definitive
radiochemotherapy for esophageal cancer. Dis Esophagus. 27:560–567.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu IC, Wu CC, Lu CY, Hsu WH, Wu MC, Lee
JY, Chou SH, Lee JM, Chou YP, Wu DC and Wu MT: Substance use
(alcohol, areca nut and cigarette) is associated with poor
prognosis of esophageal squamous cell carcinoma. PLoS One.
8:e558342013. View Article : Google Scholar : PubMed/NCBI
|
